Luxeptinib Preclinical Data Extend Potential Applications from Oncology to InflammationGlobeNewsWire • 05/02/22
Aptose to Report First Quarter 2022 Financial Results and Hold Conference Call on Monday, May 9, 2022GlobeNewsWire • 04/25/22
Aptose to Present at Canaccord Genuity's 2022 Horizons in Oncology Virtual ConferenceGlobeNewsWire • 03/31/22
Aptose Biosciences Inc. (APTO) CEO Dr. William G. Rice on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/23/22
Aptose to Report Fourth Quarter and Full Year 2021 Financial Results and Hold Conference Call on Tuesday, March 22, 2022GlobeNewsWire • 03/08/22
Aptose Shares Fall After HM43239 Data Featured At ASH Annual Meeting, Luxeptinib, APTO-253 UpdateBenzinga • 12/14/21
Implied Volatility Surging for Aptose Biosciences (APTO) Stock OptionsZacks Investment Research • 11/26/21
Aptose Biosciences Inc.'s (APTO) CEO William Rice on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/12/21
Aptose Enters into Exclusive Worldwide License Agreement with Hanmi Pharmaceutical for Clinical-Stage Myeloid Kinome Inhibitor HM43239GlobeNewsWire • 11/04/21
Aptose to Report Third Quarter 2021 Financial Results and Hold Conference Call on Thursday, November 11, 2021GlobeNewsWire • 10/26/21
Aptose Biosciences (APTO) Moves to Buy: Rationale Behind the UpgradeZacks Investment Research • 08/06/21